Company and Stock Identity

How Endeavor BioMedicines Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Watch whether the Phase 2b WHISTLE-PF result leads to a regulatory filing, and how much weight the program puts on AI imaging measurements rather than breathing tests as the trials get larger.

Endeavor BioMedicines is privately financed through venture rounds. It announced a 62 million dollar Series A in January 2021, a 101 million dollar Series B in February 2022, and a 132.5 million dollar Series C in April 2024 led by AyurMaya, an affiliate of Matrix Capital Management. Verified on the company's own media page on October 17, 2026.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Brainomix ... Company source

Brainomix CT analysis measured lung change in an Endeavor BioMedicines trial

Brainomix said on September 8, 2026 that it and Endeavor BioMedicines presented results from the ENV-IPF-101 Phase 2a trial of taladegib at the European Respiratory Society Congress 2026. Brainomix says the analysis used Brainomix 360 e-Lung for AI-powered quantitative CT analysis, and that the trial showed significant treatment effects across several measures of lung structure and fibrosis. The announcement states no regulatory status for the results.

Why it matters: Being picked as the measuring tool inside a drug trial is a different kind of credit from a sales reference, because a sponsor filing can end up resting on that measurement. The results described here belong to the trial, not to the tool, so they show the measurement moved along with the drug rather than showing e-Lung is accurate on its own in routine care. For a hospital buyer the useful question is whether trial-grade readings need trial-grade scan settings that a busy clinic will not match.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Clinical development, regulatory affairs, biometrics and data, medical affairs, and the operations roles a clinical-stage biotech needs to run multi-site trials.

Qualification signal: Lung disease trial experience is the signal that matters most here, particularly interstitial lung disease. Imaging endpoint experience is unusually relevant at this company because its trials lean on quantitative CT.

Check current roles at Endeavor BioMedicines. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Research and development leaders, clinical development teams, business development staff, and investors tracking where AI partnerships lead
Primary use case
Sponsor, license, or partner on AI research, molecule design, and trial measurement in drug development
Typical deployment
Drug developer. AI arrives through a research collaboration, a licence, or a tool used inside a clinical trial.

Evidence questions

  • What stage did the agreement reach, and were any payments or milestones disclosed?
  • Which programs or molecules does the AI work actually touch?
  • Has anything from the collaboration reached a clinical endpoint rather than a press release?

Regulatory and workflow questions

  • If AI produced a measurement used in a trial, has a regulator accepted that measurement?
  • Which regulatory submissions, if any, depend on the AI work?
  • Who is responsible for the quality of an AI-generated result inside a trial record?

Data and contract questions

  • Whose data trained the model, and what did the drug company contribute?
  • Who owns a molecule or design the collaboration produces?
  • What happens to the shared data if the collaboration ends?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources